



Comprehensive Insights into Eosinophil Interactions in Sickle Cell Anemia Severity

Emmanuel Ifeanyi Obeagu*

Department of Medical Laboratory Science, Kampala International University, Uganda

***Corresponding author:** Emmanuel Ifeanyi Obeagu, Department of Medical Laboratory Science, Kampala International University, Kampala, Uganda, Tel: +2348037369912; Email: emmanuelobeagu@yahoo.com

Review Article

Volume 8 Issue 1

Received Date: December 26, 2023

Published Date: January 17, 2024

DOI: 10.23880/hij-16000223

Abstract

Sickle Cell Anemia (SCA) is a prevalent inherited blood disorder characterized by abnormal hemoglobin leading to erythrocyte deformation and consequential vaso-occlusive events. While the primary focus has traditionally centered on the role of red blood cells in SCA pathophysiology, recent investigations have unveiled the intricate involvement of eosinophils in modulating disease severity. Eosinophils, classically recognized for their role in parasitic infections and allergic responses, have emerged as significant contributors to the inflammatory milieu and vascular dysfunction observed in SCA. This paper aims to provide an extensive understanding of the multifaceted interactions between eosinophils and the pathogenesis of sickle cell anemia, emphasizing their impact on disease severity. Insights into eosinophil biology, including their cytokine release profile, granule protein activity, and endothelial interactions, underscore their dual role in both propagating and modulating inflammation in the context of SCA. The complex interplay between eosinophils and the inflammatory microenvironment in SCA dictates disease severity, warranting a deeper understanding of these interactions for the development of targeted therapeutic strategies. In conclusion, this comprehensive review consolidates current knowledge regarding eosinophil involvement in sickle cell anemia severity, emphasizing the necessity for further investigations into specific eosinophilic mechanisms. A deeper comprehension of eosinophilic contributions to SCA pathophysiology presents a pathway toward novel therapeutic modalities, ultimately enhancing the management and prognosis of individuals afflicted with this challenging hematologic disorder.

Keywords: Sickle Cell Anemia; Eosinophils; Disease Severity; Inflammation; Immune Modulation; Vascular Dysfunction; Therapeutic Targets

Abbreviations: SCA: Sickle Cell Anemia; ECP: Eosinophil Cationic Protein; MBP: Major Basic Protein; IL: Interleukins.

Introduction

Sickle Cell Anemia (SCA) stands as a paradigmatic hemoglobinopathy characterized by a point mutation in the beta-globin gene, resulting in the synthesis of abnormal

hemoglobin HbS. This structural alteration triggers the polymerization of hemoglobin molecules under hypoxic conditions, prompting red blood cells to assume a sickle shape. This hallmark feature underlies the pathophysiology of SCA, manifesting in chronic hemolytic anemia, vaso-occlusive crises, and end-organ damage, significantly impacting patients' quality of life [1-8]. Traditionally, the focus of research and therapeutic strategies in SCA has

primarily revolved around understanding the erythrocyte-centric aspects of the disease. However, recent scientific inquiries have unveiled an intricate interplay between the immune system and the progression of SCA, particularly highlighting the contributions of eosinophils in influencing disease severity.

Eosinophil's, a specialized subset of granulocytes classically associated with allergic responses and defense against parasitic infections, have surfaced as pivotal mediators in the multifaceted landscape of sickle cell anemia [9]. While initially overshadowed by the dominance of red blood cell aberrations, eosinophils have garnered attention due to their involvement in modulating inflammatory responses, immune dysregulation, and endothelial dysfunction, thereby significantly impacting the clinical course of SCA [10].

This paper aims to delve into the burgeoning field of eosinophil research within the context of sickle cell anemia, elucidating the multifarious roles played by eosinophils in shaping disease severity. By exploring the intricate interactions between eosinophils and various pathological mechanisms underlying SCA, this review endeavors to provide a comprehensive understanding of how eosinophils contribute to the intricate tapestry of SCA pathophysiology. Overall, this paper amalgamates existing knowledge and recent research findings to shed light on the emerging significance of eosinophils in influencing the clinical course of sickle cell anemia. By elucidating the nuanced interactions between eosinophils and SCA pathogenesis, this review aims to underscore the imperative need for further investigations to unlock novel therapeutic opportunities and enhance patient care in the realm of sickle cell disease.

Eosinophils in SCA

Sickle Cell Anemia (SCA), a complex genetic disorder characterized by the presence of abnormal hemoglobin, primarily affects red blood cells, leading to their characteristic sickle-shaped appearance. While erythrocyte abnormalities have been the central focus in understanding SCA pathophysiology, recent investigations have shed light on the intricate involvement of eosinophils, a subset of white blood cells, in contributing to the disease's clinical manifestations and severity [11-17]. Studies have consistently reported elevated eosinophil counts in individuals with SCA [18,19]. This heightened presence of eosinophils suggests their active participation in the disease process. However, the specific mechanisms governing their recruitment and activation within the context of SCA remain areas of active research. Eosinophils are known for their ability to secrete an array of inflammatory mediators and cytokines, including leukotrienes, interleukins (IL-4, IL-13), and granule proteins (major basic protein - MBP-1, eosinophil cationic protein

- ECP). These molecules play pivotal roles in promoting inflammation and tissue damage, potentially exacerbating the pathophysiology of SCA [20].

The interaction between eosinophils and immune cells within the inflammatory microenvironment of SCA contributes to altered immune responses. Eosinophils possess both pro-inflammatory and anti-inflammatory properties, participating in the modulation of T-cell responses and impacting the overall immune landscape in SCA [21,22]. Eosinophils are implicated in inducing endothelial dysfunction by promoting oxidative stress and expression of adhesion molecules. In the context of SCA, these interactions might exacerbate vaso-occlusive events, thus contributing to tissue ischemia and subsequent organ damage [23]. Eosinophils have been associated with promoting thrombotic events by influencing platelet activation and aggregation, potentially exacerbating vaso-occlusive crises, one of the hallmark complications of SCA [24]. While erythrocyte abnormalities remain central to SCA, the emerging significance of eosinophils in inflammation, immune modulation, endothelial dysfunction, and vaso-occlusive events underscores their multifaceted role in shaping the disease's clinical manifestations and severity. Further investigations into eosinophil-related mechanisms hold promise for developing novel therapeutic strategies to improve outcomes for individuals affected by SCA.

Inflammation and Immune Modulation

In Sickle Cell Anemia (SCA), the interplay between inflammation and immune responses significantly contributes to disease pathogenesis and severity. Eosinophils, a subset of white blood cells, are increasingly recognized for their dual role in propagating inflammation and modulating immune responses, thereby influencing the clinical course of SCA [25-30]. Eosinophils actively participate in the inflammatory cascade by releasing a spectrum of pro-inflammatory mediators such as leukotrienes, cytokines (IL-4, IL-13), and granule proteins (MBP-1, ECP). These molecules are implicated in enhancing inflammation, exacerbating tissue injury, and potentially intensifying the vaso-occlusive events characteristic of SCA [31]. Eosinophils possess the ability to modulate immune responses by influencing the activity of T-cells and other immune cells. They contribute to immune dysregulation observed in SCA, altering the immune landscape and exacerbating the inflammatory milieu within the affected tissues and vasculature [32]. While known for their pro-inflammatory functions, eosinophils also exhibit anti-inflammatory properties. They can contribute to the resolution of inflammation by promoting the clearance of cellular debris and participating in tissue repair processes. However, in the context of SCA, dysregulated eosinophilic responses may tip the balance towards sustained

inflammation, perpetuating tissue damage and disease progression [31].

Eosinophils' interactions with endothelial cells play a pivotal role in endothelial activation. This interaction triggers the expression of adhesion molecules and induces oxidative stress, contributing to endothelial dysfunction observed in SCA. The resultant endothelial activation further amplifies the inflammatory responses, promoting vaso-occlusive events and tissue ischemia [33-36]. Eosinophils influence the cytokine milieu within the inflammatory microenvironment. Their secretion of specific cytokines contributes to the complex cytokine network in SCA, affecting the balance between pro-inflammatory and anti-inflammatory signals, consequently influencing disease severity. Eosinophils, through their involvement in modulating inflammatory responses and immune dysregulation, significantly impact the pathogenesis and progression of Sickle Cell Anemia. Further exploration into the specific mechanisms by which eosinophils contribute to inflammation and immune modulation in SCA is essential for developing targeted therapies to mitigate the inflammatory burden and improve clinical outcomes for individuals affected by this challenging hematological disorder.

Vascular Dysfunction and Endothelial Interactions

The pathophysiology of Sickle Cell Anemia (SCA) extends beyond erythrocyte abnormalities, encompassing vascular dysfunction and endothelial interactions. Eosinophils, a subset of white blood cells, are implicated in promoting endothelial dysfunction, thereby exacerbating vascular complications observed in SCA [36-40]. Eosinophils contribute to endothelial activation by inducing oxidative stress and promoting the expression of adhesion molecules on endothelial surfaces. This endothelial activation, observed in SCA, enhances the adhesive properties of endothelial cells, facilitating the adherence of sickle cells and other blood components, consequently contributing to vaso-occlusive events [41]. The interaction between eosinophils and endothelial cells leads to the generation of oxidative stress within the vascular microenvironment. This oxidative stress, coupled with inflammatory mediators released by eosinophils, further amplifies endothelial dysfunction, exacerbating tissue damage and promoting vaso-occlusive crises in SCA [23].

Eosinophils' involvement in inducing endothelial dysfunction and enhancing adhesion molecule expression contributes significantly to the pathogenesis of vaso-occlusive events in SCA. These events, characterized by the occlusion of blood vessels by sickled red blood cells, further propagate tissue ischemia and organ damage, hallmark features of

SCA complications [23]. Eosinophils are implicated in promoting thrombotic events through interactions with platelets and their ability to activate coagulation pathways. In SCA, dysregulated eosinophil-platelet interactions may contribute to the pro-thrombotic milieu, exacerbating the propensity for thrombotic complications [42]. Eosinophils may impact vascular tone and blood flow regulation by contributing to endothelial dysfunction. This influence on vascular physiology can further compound the vascular complications seen in SCA, contributing to tissue ischemia and end-organ damage. Eosinophils, through their interactions with endothelial cells and their contributions to endothelial dysfunction, significantly impact vascular complications in Sickle Cell Anemia. Further elucidation of the molecular mechanisms governing eosinophil-endothelial interactions in SCA is crucial for the development of targeted interventions aimed at preserving vascular function and mitigating the detrimental consequences of vascular dysfunction in individuals affected by this challenging hematologic disorder.

Therapeutic Implications and Future Directions

The emerging understanding of eosinophils' multifaceted involvement in SCA pathophysiology has opened avenues for potential therapeutic interventions aimed at mitigating disease severity. Exploring strategies targeting eosinophil-related pathways presents promising prospects for improving clinical outcomes and managing complications associated with SCA. Developing therapies specifically targeting eosinophils holds potential in attenuating their deleterious effects in SCA. Eosinophil-lowering agents or inhibitors targeting eosinophil activation and recruitment pathways could help alleviate inflammatory burden and mitigate tissue damage associated with eosinophilic responses. Given the significant contribution of eosinophils to the inflammatory milieu in SCA, anti-inflammatory agents targeting pathways influenced by eosinophil-derived mediators (leukotrienes, cytokines) could help dampen the excessive inflammatory response, thereby reducing tissue injury and vaso-occlusive events. Adopting precision medicine strategies to identify individuals with heightened eosinophil-mediated complications might aid in tailoring therapeutic interventions. This personalized approach could involve identifying biomarkers or genetic profiles indicative of increased eosinophil activity to guide targeted therapies for specific patient subsets.

Therapeutic strategies focused on preserving endothelial function and mitigating endothelial activation induced by eosinophils could prove beneficial. Agents targeting oxidative stress, adhesion molecule expression, and endothelial repair mechanisms might help improve vascular health and reduce

vaso-occlusive events in SCA. Continued research into the specific molecular pathways governing eosinophil-mediated effects in SCA is essential. Identifying novel therapeutic targets, such as signaling pathways involved in eosinophil-endothelial interactions or immune modulation, could lead to the development of innovative therapies for managing SCA complications. Conducting well-designed clinical trials focusing on eosinophil-targeted therapies or anti-inflammatory interventions in SCA is crucial for translating preclinical findings into effective treatments. Collaborative efforts between basic research and clinical trials are imperative to evaluate the safety and efficacy of potential therapies. Enhancing patient care by integrating novel therapeutic approaches into comprehensive management strategies is pivotal. Holistic care that encompasses traditional disease-modifying therapies alongside emerging eosinophil-targeted interventions could significantly improve the quality of life for individuals living with SCA.

Conclusion

The intricate interplay between eosinophils and Sickle Cell Anemia (SCA) pathophysiology has unveiled a new dimension in understanding the disease's complexity beyond erythrocyte abnormalities. Eosinophils, traditionally recognized for their roles in allergic responses and immune defense, have emerged as significant contributors to inflammation, immune dysregulation, vascular dysfunction, and disease severity in SCA. Therapeutically targeting eosinophil-related pathways presents a promising approach to attenuate the inflammatory burden, mitigate endothelial dysfunction, and improve clinical outcomes in individuals affected by SCA. Strategies such as eosinophil-lowering agents, anti-inflammatory therapies, precision medicine approaches, and endothelial protection strategies offer potential avenues for intervention.

Understanding the intricate interactions between eosinophils and SCA pathophysiology is critical for unraveling novel therapeutic targets and enhancing patient care. Advancements in eosinophil-related research hold promise in revolutionizing the management of Sickle Cell Anemia, paving the way for tailored interventions that alleviate disease severity and improve the quality of life for individuals living with this challenging hematologic disorder.

References

- Obeagu EI, Ochei KC, Nwachukwu BN, Nchuma BO (2015) Sickle cell anaemia: a review. *Sch J App Med Sci* 3(6B): 2244-2252.
- Obeagu EI (2020) Erythropoietin in Sickle Cell Anaemia: A Review. *IJRSMHS* 5(2): 22-28.
- Obeagu EI (2018) Sickle Cell Anaemia: Haemolysis and Anemia. *Int J Curr Res Chem Pharm Sci* 5(10): 20-21.
- Obeagu EI, Muhimbura E, Kagenderezo BP, Uwakwe OS, Nakyeyune S, et al. (2022) An Update on Interferon Gamma and C Reactive Proteins in Sickle Cell Anaemia Crisis. *J Biomed Sci* 11(10): 84.
- Obeagu EI, Bunu UO, Obeagu GU, Habimana JB (2023) Antioxidants in the management of sickle cell anaemia: an area to be exploited for the wellbeing of the patients. *International Research in Medical and Health Sciences* 6(4): 12-17.
- Obeagu EI, Ogunnaya FU, Obeagu GU, Ndidi AC. Sickle cell anaemia: a gestational enigma. (2023) *European Journal of Biomedical and Pharmaceutical Sciences* 10((9): 72-75
- Obeagu EI (2018) An update on micro RNA in sickle cell disease. *Int J Adv Res Biol Sci* 5: 157-158.
- Obeagu EI, Babar Q (2021) Covid-19 and Sickle Cell Anemia: Susceptibility and Severity. *J Clinical and Laboratory Research* 4(1): 56
- Tolksdorf C, Moritz E, Wolf R, Meyer U, Marx S, et al. (2023) Platelet-derived s1p and its relevance for the communication with immune cells in multiple human diseases. *Int J Mol Sci* 23(18): 10278.
- Mantovani A, Dinarello CA, Molgora M, Garlanda C (2019) Interleukin-1 and related cytokines in the regulation of inflammation and immunity. *Immunity* 50(4): 778-795.
- Obeagu EI (2023) Depression in Sickle Cell Anemia: An Overlooked Battle. *Int J Curr Res Chem Pharm Sci* 10(10): 41-44.
- Obeagu EI, Obeagu GU (2023) Evaluation of Hematological Parameters of Sickle Cell Anemia Patients with Osteomyelitis in A Tertiary Hospital in Enugu, Nigeria. *Journal of Clinical and Laboratory Research* 6(1): 94.
- Obeagu EI, Dahir FS, Francisca U, Vandu C, Obeagu GU et al. (2023) Hyperthyroidism in sickle cell anaemia. *Int J Adv Res Biol Sci* 10(3): 81-89.
- Obeagu EI, Obeagu GU, Akinleye CA, Igwe MC (2023) Nosocomial infections in sickle cell anemia patients: Prevention through multi-disciplinary approach: A review. *Medicine* 102(48): e36462.
- Njar VE, Ogunnaya FU, Obeagu EI (2023) Knowledge and Prevalence of the Sickle Cell Trait among Undergraduate Students of the University of Calabar. *Prevalence* 5(100):

- 5.
16. Swem CA, Ukaejiofo EO, Obeagu EI, Eluke B (2018) Expression of micro RNA 144 in sickle cell disease. *Int J Curr Res Med Sc* 4(3): 26-32.
17. Obeagu EI, Nimo OM, Bunu UO, Ugwu OP, Alum EU (2023) Anaemia in children under five years: African perspectives. *Int J Curr Res Biol Med* 1: 1-7.
18. Pallis FR, Conran N, Fertrin KY, Saad STO, Costa FF, et al. (2014) Hydroxycarbamide reduces eosinophil adhesion and degranulation in sickle cell anaemia patients. *British Journal of Haematology* 164(2): 286-295.
19. Hartl S, Breyer MK, Burghuber OC, Ofenheimer A, Schrott A, et al. (2020) Blood eosinophil count in the general population: typical values and potential confounders. *Eur Respir J* 55(5): 1901874
20. Wechsler ME, Munitz A, Ackerman SJ, Drake MG, Jackson DJ, et al. (2021) Eosinophils in health and disease: a state-of-the-art review. *Mayo Clin Proc* 96 (10): 2694-2707.
21. Zhen Y, Shu W, Hou X, Wang Y (2021) Innate immune system orchestrates metabolic homeostasis and dysfunction in visceral adipose tissue during obesity. *Frontiers in Immunology* 12: 702835.
22. Simoes FC, Riley PR (2022) Immune cells in cardiac repair and regeneration. *Development* 149(8): 199906.
23. Cook JMM, Marchese ME, Abdala VH (2011) Vascular cell adhesion molecule-1 expression and signaling during disease: regulation by reactive oxygen species and antioxidants. *Antioxidants Redox Signal* 15(6): 1607-1638.
24. Azevedo DJT, Malmegrim KC (2020) Immune mechanisms involved in sickle cell disease pathogenesis: current knowledge and perspectives. *Immunol Lett* 224: 1-11.
25. Obeagu EI (2018) Sickle cell anaemia: Historical perspective, Pathophysiology and Clinical manifestations. *Int J Curr Res Chem Pharm Sci* 5(11): 13-15.
26. Obeagu EI, Obeagu GU (2023) Sickle Cell Anaemia in Pregnancy: A Review. *International Research in Medical and Health Sciences* 6(2): 10-13.
27. Obeagu EI, Mohamad AH. An update on Iron deficiency anaemia among children with congenital heart disease. *Int J Curr Res Chem Pharm Sci* 10(4): 45-48.
28. Edward U, Osuorji VC, Nnodim J, Obeagu EI (2022) Evaluation of Trace Elements in Sickle Cell Anaemia Patients Attending Imo State Specialist Hospital, Owerri. *Madonna University Journal of Medicine and Health Sciences* 2(1): 218-234.
29. Umar MI, Aliyu F, Abdullahi MI, Aliyu MN, Isyaku I, et al. (2023) Assessment Of Factors Precipitating Sickle Cell Crises Among Under 5-Years Children Attending Sickle Cell Clinic Of Murtala Muhammad Specialist Hospital, Kano. *Blood* 11:16.
30. Obeagu EI (2018) Vaso-occlusion and adhesion molecules in sickle cells disease. *Int J Curr Res Med Sci* 4(11): 33-35.
31. Vatrella A, Maglio A, Pelaia C, Ciampo L, Pelaia G, et al. (2022) Eosinophilic inflammation: An appealing target for pharmacologic treatments in severe asthma. *Biomedicine* 10(9): 2181.
32. Spencer LA, Weller PF (2010) Eosinophils and Th2 immunity: contemporary insights. *Immunol Cell Biol* 88(3): 250-256.
33. Aloh GS, Obeagu, EI, Okoroiwu IL, Odo, C, Ugwu GU et al. (2015) Antioxidant-Mediated Heinz Bodies Levels of Sickle Erythrocytes under Drug-Induced Oxidative Stress. *European Journal of Biomedical and Pharmaceutical Sciences* 2(1): 502-507.
34. Obeagu EI, Malot S, Obeagu GU, Ugwu OP (2023) HIV resistance in patients with Sickle Cell Anaemia. *NIJSES* 3(2): 56-59.
35. Obeagu EI, Bot YS, Opoku D, Obeagu GU, Hassan AO (2023) Sickle Cell Anaemia: Current Burden in Africa. *International Journal of Innovative and Applied Research* 11(2): 12-14.
36. Obeagu EI, Ogbuabor BN, Ikechukwu OA, Chude CN (2014) Haematological parameters among sickle cell anemia patients' state and haemoglobin genotype AA individuals at Michael Okpara University of Agriculture, Umudike, Abia State, Nigeria. *Int J Curr Microbiol App Sci* 3(3): 1000-1005.
37. Obeagu EI, Abdirahman BF, Bunu UO, Obeagu GU (2023) Obstetrics characteristics that effect the newborn outcomes. *Int J Adv Res Biol Sci* 10(3): 134-143.
38. Obeagu EI, Opoku D, Obeagu GU (2023) Burden of nutritional anaemia in Africa: A Review. *Int J Adv Res Biol Sci* 10(2): 160-163.
39. Ifeanyi E (2015) Erythropoietin (Epo) Level in Sickle Cell Anaemia (HbSS) With Falciparum Malaria Infection in University Health Services, Michael Okpara University of

- Agriculture, Umudike, Abia State, Nigeria. Paripex Indian Journal Of Research 4(6): 258-259
40. Ifeanyi OE, Stanley MC, Nwakaego OB (2014) Comparative analysis of some haematological parameters in sickle cell patients in steady and crisis state at Michael Okpara University of agriculture, Umudike, Abia state, Nigeria. Int J Curr Microbiol App Sci 3(3): 1046-1050.
 41. Ifeanyi EO, Uzoma GO (2020) Malaria and The Sickle Cell Trait: Conferring Selective Protective Advantage to Malaria. J Clin Med Res 2: 1-4.
 42. Zetter B (2023) The ability for cells to harness alternative splicing enables them to diversify their proteome in order to carry out complex biological functions and adapt to external and internal stimuli. The spliceosome is the multiprotein-RNA complex charged with the intricate task of alternative splicing. Aberrant splicing can arise from abnormal spliceosomes or splicing factors and drive cancer development and progression. This review will provide an. Reviews in Molecular and Cellular Oncology pp: 44.

